Regimen simplification in MDR/RR-TB following the PROSPECT trial

This publication has 10 references indexed in Scilit:

• Individualized TB care for drug-susceptible pulmonary tuberculosis: clinical alternatives when HRZE is contraindicated or not tolerated
  Expert Review of Respiratory Medicine, 2026
• Efficacy and safety of a 4-month quabodepistat, delamanid, and bedaquiline regimen for drug-susceptible pulmonary tuberculosis: a multicentre, open-label, randomised, proof-of-concept, non-inferiority, phase 2b/c trial
  The Lancet Infectious Diseases, 2026
• Evaluation of an oral bedaquiline regimen for treating multidrug-resistant TB in China: a randomized trial
  Infection, 2026
• Static vs. cidal: it’s not complex; it’s simply incorrect
  Antimicrobial Agents and Chemotherapy, 2025
• Effectiveness of the Bedaquiline, Pretomanid, and Linezolid Regimen, With or Without Moxifloxacin, for Drug-Resistant Tuberculosis in Ukraine Under Programmatic Conditions
  Clinical Infectious Diseases, 2025
• Updates on the Treatment of Drug-Susceptible and Drug-Resistant Tuberculosis: An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline
  American Journal of Respiratory and Critical Care Medicine, 2025
• Treatment Outcomes and Adverse Drug Effects of Ethambutol, Cycloserine, and Terizidone for the Treatment of Multidrug-Resistant Tuberculosis in South Africa
  Antimicrobial Agents and Chemotherapy, 2020
• Cost-effectiveness of bedaquiline in MDR and XDR tuberculosis in Italy
  Journal of Market Access & Health Policy, 2017
• Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis
  Clinical Infectious Diseases, 2016
• The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells
  Nature Reviews Microbiology, 2014